Researchers at Texas A&M University say they have done something the human brain was long thought incapable of: rolled back the cellular clock on aging — with two squirts of a nasal spray.
In findings published in the Journal of Extracellular Vesicles and highlighted on May 26, 2026, scientists at the university's Institute for Regenerative Medicine reported that an experimental intranasal therapy reduced chronic brain inflammation, restored mitochondrial function, and significantly improved memory in test animals after just two doses. The benefits, they say, lasted for months.
Fighting "neuroinflammaging"
The therapy targets a process scientists call neuroinflammaging — low-grade chronic inflammation in the aging brain. Over time, that simmering immune activity disrupts memory and learning, and is increasingly seen as a major driver of dementia and Alzheimer's disease.
"Brain age-related diseases like dementia are a major health concern worldwide," said Dr. Ashok Shetty, the university distinguished professor who led the study. "What we're showing is brain aging can be reversed, to help people stay mentally sharp, socially engaged and free from age-related decline."
How the spray works
The treatment relies on tiny biological capsules called extracellular vesicles (EVs), naturally produced by cells to ferry genetic material around the body. The Texas A&M team loaded these vesicles with specific microRNAs — molecules that regulate gene activity — and delivered them through the nose.
That route matters. Nasal delivery sidesteps the blood-brain barrier, the protective shield that blocks most drugs from reaching brain tissue. "Intranasal delivery allows us to reach, and treat, the brain directly without invasive procedures," said senior research scientist Dr. Maheedhar Kodali.
Once inside the brain, the microRNAs shut down two key inflammatory pathways — the NLRP3 inflammasome and cGAS-STING signaling — that drive chronic aging-related inflammation. They also reactivated mitochondria, the cellular power plants that produce energy. As mitochondria recover, neurons regain the ability to process and store information.
"We are giving neurons their spark back by reducing oxidative stress and reactivating the brain's mitochondria," said Dr. Madhu Leelavathi Narayana, a co-senior author of the study.
Memory measurably restored
The team measured not just biology but behavior. Treated animals performed significantly better on learning and memory tests than untreated controls of the same age. Effects were visible within weeks and persisted long after dosing ended — a signal that the spray may be triggering a durable shift in brain biology, not just a temporary tune-up.
A long road, but a hopeful one
The findings are still preclinical, and human trials will need to confirm safety and efficacy. But the team is optimistic. The approach is non-invasive, the components are biologically familiar, and the manufacturing process for vesicle-based therapeutics is already maturing thanks to cancer and vaccine research.
"As we develop and scale this therapy, a simple, two-dose nasal spray could one day replace invasive, risky procedures or maybe even months of medication," Shetty said.
For an aging global population facing skyrocketing rates of dementia, the idea that a few sprays might one day help keep the mind sharp is exactly the kind of low-friction breakthrough public health desperately needs. The work is funded in part by the National Institute on Aging.
